Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

No abstract is available for this paper.

• Publication year

  2012

• Venue

  mAbs

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/mabs.4.2.19387PMID 22453096PMCID PMC3361660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.

  2011cited by this paper
• Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

  2011cited by this paper
• Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

  2011cited by this paper
• Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

  2011cited by this paper
• Microneedle-Based Intradermal Delivery Enables Rapid Lymphatic Uptake and Distribution of Protein Drugs

  2010cited by this paper
• Reduced elimination of IgG antibodies by engineering the variable region.

  2010cited by this paper
• Genetic management of the Göttingen Minipig population.

  2010cited by this paper
• Welfare of the minipig with special reference to use in regulatory toxicology studies.

  2010cited by this paper
• Effects of charge on antibody tissue distribution and pharmacokinetics.

  2010cited by this paper
• The Role of Pharmacokinetics and Pharmacodynamics in Selecting a Relevant Species

  2010cited by this paper
• Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products.

  2010cited by this paper
• The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment.

  2010cited by this paper
• Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited

  2010cited by this paper
• Minipig, minipig, let me in

  2010cited by this paper
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

  2010cited by this paper
• Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

  2010cited by this paper
• Subcutaneous administration of biotherapeutics: current experience in animal models.

  2010influential reference
• Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

  2009cited by this paper
• Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

  2009cited by this paper
• Neonatal FcR Expression in Bone Marrow-Derived Cells Functions to Protect Serum IgG from Catabolism1

  2007cited by this paper
• Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy

  2007cited by this paper
• Full-length antibodies on display

  2007cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Clinical Assessment of Human Lymph Flow Using Removal Rate Constants of Interstitial Macromolecules: A Critical Review of Lymphoscintigraphy

  2007cited by this paper
• Interspecies Comparisons of Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin

  2007cited by this paper
• Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

  2007cited by this paper
• Quantitative imaging of lymph function.

  2007cited by this paper
• Preclinical safety testing of monoclonal antibodies: the significance of species relevance

  2007cited by this paper
• Use of nontraditional animals for evaluation of pharmaceutical products

  2006cited by this paper
• Elimination mechanisms of therapeutic monoclonal antibodies.

  2006cited by this paper
• Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

  2006cited by this paper
• Subcutaneous drug delivery and the role of the lymphatics.

  2005cited by this paper
• Presence of the di-leucine motif in the cytoplasmic tail of the pig FcRn alpha chain.

  2003cited by this paper
• Presence of the di-leucine motif in the cytoplasmic tail of the pig FcRn α chain

  2003cited by this paper
• Structure of the rat subcutaneous connective tissue in relation to its sliding mechanism.

  2003cited by this paper
• Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection.

  2003cited by this paper
• Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin

  2002cited by this paper
• A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

  2002cited by this paper
• Transport and absorption of drugs via the lymphatic system.

  2001cited by this paper
• Evaluation of Göttingen minipig skin for transdermal in vitro permeation studies.

  2000cited by this paper
• Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.

  2000cited by this paper
• Lymphatic transport of proteins after subcutaneous administration.

  2000cited by this paper
• Transcutaneous immunization of domestic animals: opportunities and challenges.

  2000cited by this paper
• Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing.

  1999cited by this paper
• Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans.

  1999cited by this paper
• Transdermal testosterone delivery in castrated Yucatan minipigs: pharmacokinetics and metabolism.

  1998cited by this paper
• Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs.

  1998cited by this paper
• Increasing the serum persistence of an IgG fragment by random mutagenesis

  1997cited by this paper
• Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching.

  1996cited by this paper
• Flow velocity of single lymphatic capillaries in human skin.

  1996cited by this paper
• Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice.

  1994cited by this paper
• Flow velocity in the superficial lymphatic network of the mouse tail.

  1994cited by this paper
• Antidiuretic hormone and exocytosis: lessons from neurosecretion.

  1994cited by this paper
• Catabolism of the Murine IgGl Molecule: Evidence that Both CH2‐CH3 Domain Interfaces are Required for Persistence of IgGl in the Circulation of Mice

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts.

  1991cited by this paper
• The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh

  1991cited by this paper
• Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

  1986cited by this paper
• Methods for in vitro percutaneous absorption studies. II. Animal models for human skin.

  1982cited by this paper
• THE PANNICULUS CARNOSUS IN THE DOMESTIC PIC

  1977cited by this paper
• Society of Toxicology

  1964cited by this paper

• Near UV and Visible Light-Induced Degradation of IgG2: Photo-Fenton Reaction in Citrate Buffer.

  2026cites this paper
• High concentration subcutaneous biological drug products: challenges and advancements.

  2026cites this paper
• Quantitative Prediction of Human Pharmacokinetics for Fc‐Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection

  2026influential citation
• In Vitro and in Vivo Relationship of Subcutaneous Absorption of Therapeutic Proteins

  2025cites this paper
• Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A

  2025cites this paper
• Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.

  2025cites this paper
• Assessment of Minipigs as a Non-clinical Model for Screening and Derisking Injection Site Reactions in Clinical Trials

  2025cites this paper
• Considerations for Use of Humanized IgG1/4 Göttingen Minipigs in Safety Assessment of Antibody-Based Therapeutics.

  2025cites this paper
• Development of an ex vivo human skin model and evaluation of biological responses to subcutaneously injected hyaluronic acid formulations.

  2025cites this paper
• A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics

  2024cites this paper
• R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases

  2024cites this paper
• Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal Antibodies

  2024cites this paper
• Development and Evaluation of Five-in-One Vaccine Microneedle Array Patch for Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae Type b: Immunological Efficacy and Long-Term Stability

  2024cites this paper
• Comparative pharmacokinetics of porcine and human anti-influenza hemagglutinin monoclonal antibodies in outbred pigs and minipigs

  2024cites this paper
• Opportunities and Challenges for Use of Minipigs in Nonclinical Pharmaceutical Development: Results of a Follow-Up IQ DruSafe Survey.

  2024cites this paper
• A pilot pharmacokinetic and Metabolite identification study of Erinacine A in a Single landrace pig model

  2024cites this paper
• Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution.

  2024cites this paper
• A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph Nodes

  2024cites this paper
• Prediction of subcutaneous drug absorption - Development of novel simulated interstitial fluid media for predictive subcutaneous in vitro assays.

  2024cites this paper
• In Vitro and In Vivo Hydrolytic Degradation Behaviors of a Drug-Delivery System Based on the Blend of PEG and PLA Copolymers

  2023cites this paper
• Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics

  2023cites this paper
• Development of an ex vivo porcine skin model for the preclinical evaluation of subcutaneously injected biomacromolecules.

  2023cites this paper
• A Quantitative Prediction Method for the Human Pharmacokinetics of Fc-Fusion Proteins

  2023cites this paper
• Characterization of large volume subcutaneous injections using computed tomography imaging and simultaneous pressure measurements

  2023cites this paper
• Prediction of subcutaneous drug absorption - characterization of subcutaneous interstitial fluids as a basis for developing biorelevant in vitro models.

  2023cites this paper
• Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies

  2023cites this paper
• Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties

  2022cites this paper
• Biotherapeutics ADME and PK/PD Principles

  2022cites this paper
• Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models

  2022cites this paper
• Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

  2022cites this paper
• Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness

  2022cites this paper
• Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model

  2022cites this paper
• Characterization of pig skin microbiome and appraisal as an in vivo subcutaneous injection model

  2022influential citation
• Göttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation.

  2022cites this paper
• Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection

  2022influential citation
• Characterization of the immune system of Ellegaard Göttingen Minipigs - An important large animal model in experimental medicine

  2022cites this paper
• Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics

  2022cites this paper
• C-Terminal Lysine Processing of IgG in Human Suction Blister Fluid: Implications for Subcutaneous Administration.

  2022cites this paper
• D-VITylation: Harnessing the biology of vitamin D to improve the pharmacokinetic properties of peptides and small proteins.

  2022cites this paper
• Multi-omics approaches for comprehensive analysis and understanding of the immune response in the miniature pig breed

  2022cites this paper
• Evaluation of in vitro tools to predict the in vivo absorption of biopharmaceuticals following subcutaneous administration.

  2022cites this paper
• Special Section on Pharmacokinetics and ADME of Biological Therapeutics – Minireview Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics

  2022cites this paper
• An inverse-breathing encapsulation system for cell delivery

  2021cites this paper
• Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.

  2021cites this paper
• Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

  2021cites this paper
• Continuous Feeding Reduces the Generation of Metabolic Byproducts and Increases Antibodies Expression in Chinese Hamster Ovary-K1 Cells

  2021cites this paper
• Intrinsic physicochemical profile of marketed antibody-based biotherapeutics

  2021cites this paper
• Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs

  2021cites this paper
• Ustekinumab pharmacokinetics after subcutaneous administration in swine model

  2021cites this paper
• Multiscale pharmacokinetic modeling of systemic exposure of subcutaneously injected biotherapeutics.

  2021cites this paper
• Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods

  2021cites this paper
• Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering

  2021cites this paper
• Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins.

  2021cites this paper
• Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies

  2021cites this paper
• A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments

  2021cites this paper
• Chapter 13: Formulation Development for Biologics Utilizing Lab Automation and In Vivo Performance Models

  2020cites this paper
• Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration.

  2020cites this paper
• Physicochemical stability of monoclonal antibodies: a review.

  2020cites this paper
• In Vivo Stability of Therapeutic Proteins

  2020cites this paper
• Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model.

  2020cites this paper
• Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans

  2020cites this paper
• Porcine cancer models: potential tools to enhance cancer drug trials

  2020cites this paper
• Predicting Method for the Human Plasma Concentration-Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates.

  2020cites this paper
• Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.

  2020cites this paper
• Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies

  2020cites this paper
• Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling

  2020cites this paper
• Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review

  2020cites this paper
• Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans

  2020cites this paper
• Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain

  2020cites this paper
• Identification and characterization of FcγRs in Göttingen minipigs – implications for preclinical assessment of therapeutic antibodies

  2019cites this paper
• Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response.

  2019cites this paper
• Perspectives From the 12th Annual Minipig Research Forum: Early Inclusion of the Minipig in Safety Assessment Species Selection Should be the Standard Approach

  2019cites this paper
• Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics

  2019cites this paper
• Göttingen Minipigs as Large Animal Model in Toxicology

  2019cites this paper
• Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems

  2019cites this paper
• Tau antibody chimerization alters its charge and binding, thereby reducing its cellular uptake and efficacy

  2019cites this paper
• The Binding of Human IgG to Minipig FcγRs – Implications for Preclinical Assessment of Therapeutic Antibodies

  2019cites this paper
• In vitro models for immunogenicity prediction of therapeutic proteins

  2018cites this paper
• Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

  2018cites this paper
• Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice

  2018cites this paper
• Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing

  2018cites this paper
• In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies

  2018cites this paper
• Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.

  2018cites this paper
• Switching from an IV to an SC Formulation—Considerations for Formulation Development and Formulation Bridging

  2018cites this paper
• Therapeutic protein aggregates: biophysical characterization and in vitro modelisation of subcutaneous tissue

  2018cites this paper
• Future of Regulatory Safety Assessments

  2018cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies

  2018cites this paper
• Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective

  2018cites this paper
• Subcutaneous delivery of monoclonal antibodies: How do we get there?

  2018cites this paper
• The Development of Methods to Account for Physiologic Dynamic Changes and Their Effects on the Pharmacokinetics of Therapeutic Monoclonal Antibodies and other Therapeutics

  2017cites this paper
• Modification of the Fc Region of a Human Anti‐oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half‐life in Cynomolgus Monkeys

  2017cites this paper
• Preliminary study of the safety and efficacy of medium-chain triglycerides for use as an intraocular tamponading agent in minipigs

  2017cites this paper
• Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins

  2017cites this paper
• Systemic effects in naïve mice injected with immunomodulatory lectin ArtinM

  2017cites this paper
• Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers

  2017cites this paper
• Pharmacokinetics of Monoclonal Antibodies

  2017cites this paper
• Minipigs in Translational Immunosafety Sciences

  2016cites this paper
• Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.

  2016cites this paper
• In-Silico Methods for De-Risking the Clinical Development of Subcutaneously Administered Therapeutic Macromolecules

  2016cites this paper